Loading clinical trials...
Loading clinical trials...
Randomised, Double Blind, Placebo-controlled Dose Ranging Trial to Determine the Antiviral Activity and Safety of Alovudine in Nucleoside-experienced HIV-infected Subjects Experiencing Virologic Failure
Conditions
Interventions
Alovudine - low
Alovudine - medium
+2 more
Start Date
April 1, 2004
Primary Completion Date
December 1, 2004
Last Updated
September 5, 2014
NCT06694805
NCT04142047
NCT07428330
NCT07225530
NCT06665646
NCT05897099
Lead Sponsor
Boehringer Ingelheim
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions